摘要
目的研究神经元特异性烯醇化酶（NSE）对尼莫地平治疗急性脑血管病的疗效评价。方法42例临床确诊为急性脑血管病的患者随机分为3组治疗组（A、B、C组）和对照组（D组）。对照组常规治疗，治疗组在对照组治疗的基础上分别在入院12h内，48h，5d开始给予尼莫地平针（约为15μg·kg^-1·h^-1）加入5％葡萄糖注射液500ml中静滴，每日1次，共15d。每组抽取6例分别用酶联免疫（ELISA）法监测入院时、48h、5d、7d、10d的NSE水平，进行统计分析。结果48h内静滴尼莫地平对脑血管病NSE的水平较对照组明显降低，差异有统计学意义（Jp〈0．05）。结论尼莫地平治疗急性脑血管病有较好临床疗效，早期（48h内）静滴疗效更佳。
Objective To explore the role of neuron specific enolase （NSE） in the evaluation of the efficacy of nimodipine for acute cerebrovascular disease. Methods 42 patients with clinically confirmed acute cerebrovascular disease were randomly assigned to receive conventional therapy （control group）, or conventional therapy combined with intravenous nimodipine （15μgkg^-1· h^-1） plus 5% glucose of 500 ml （study group） once a day for 15 days. The treatment started within 12, 48 hour, and 5 days of admission. NSE levels were detected by ELISA on admission and 48hour, days 5, 7, and 10. The data were analyzed statistically. Results After treatment with intravenous nimodipine within 48 hours, NSE level was markedly lower, as compared with that in the control group （P〈 0.05）. Conclusions Nimodipine has a better efficacy in the treatment of acute cerebrovascular disease. The early use of intravenous drip （within 48 hours） is more effective.
出处
《国际医药卫生导报》
2010年第17期2129-2131,共3页
International Medicine and Health Guidance News
